---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-018725"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:36:03.911001+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics prices $18M underwritten offering of 18M shares at $1.00 per share

## Summary
- Offering of 18,000,000 common shares at $1.00 each; gross proceeds ~$18M.
- Underwriters purchase at $0.94/share; net proceeds for working capital and general corporate purposes.
- Anchored by a $15M investment from a fundamental institutional investor and support from a large existing shareholder.
- Closing expected on or about April 24, 2026, subject to customary conditions.
- Canaccord Genuity and BTIG act as joint bookrunners; shelf registration effective March 26, 2026.

## SEC filing metadata
- accession: 0001493152-26-018725
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315226018725/0001493152-26-018725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315226018725/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-018725
- JSON: https://secwatch.observer/filing/0001493152-26-018725.json
- Plain text: https://secwatch.observer/filing/0001493152-26-018725.txt

## Source-grounded claims
- claim_id: 6be7be8750def722a610b1c8cf47d04f693dc700
  claim: Lucid Diagnostics Inc. entered into Underwriting Agreement with Canaccord Genuity LLC and BTIG, LLC, as representatives of the underwriters (effective 2026-04-23).
  evidence_excerpt: On April 23, 2026, Lucid Diagnostics Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Canaccord Genuity LLC and BTIG, LLC, as representatives (the “ Representatives ”) of the underwriters named therein (the “ Underwriters ”), for an underwritten offering to the public of shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315226018725/0001493152-26-018725-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.